Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (1335)	10/6/1998 5:33:00 PM
From: Zvi Steinberg	Respond to of 1491

Gabe, I agree with your assessment. The answer regarding Co. Press release early tomorrow am Prior to convention is yes according to Gwynn Crosson. I understand you plan to attend the conference. If so, Please share your impressions. Best regards, Zvi

To: Gabe Fernandez who wrote (1335)	10/6/1998 7:14:00 PM
From: Ariella	Read Replies (2) \| Respond to of 1491

Dear Gabe -- I think HU-211 is revolutionary too! But it's the rest of the world that has to be convinced, or maybe one should say "educated." I discussed this issue with PARS today. Their task is more difficult because people don't think of head trauma in the same way that people easily think of cancer. That's why the release this week had a "factoid" on number of victims of head trauma in the US. Of course, those numbers look small relative to the number of victims one would associate with cancer. This appearance is misleading, however, because of the amplification of costs that often arise after the initial head trauma. For patients who die, life and cost of care cease at the same time. For the many who live on, costs continue -- often extremely long and expensive rehabilitation costs. This bigger number, which relates directly to the quality of life issues which HU-211 can address, is the real "story" behind PARS. One has to dig for it at this point, however. The market must be educated -- that's a function of media work for the company..... NEWSDAY, a big daily newspaper, ran a story two years ago about coma patients and the high cost of care: Here's an excerpt: _________________ Thomas Maier, Between Life and Death / The Coma Debate / Alive in a Vacuum / Coma patients surviving longer, but care is costly. SIDEBAR: Profiles of the struggle. (See end of text)., Newsday, 06-23-1996, pp A05. << Since the early 1970s, when nearly 90 percent of coma victims died at the scene, there's been a remarkable improvement in acute care. Ambulance crews now rush to keep up vital oxygen supplies to each accident victim's brain. Emergency room doctors rely on high-tech methods, like CAT scans, and newly developed drugs to minimize further damage. Once coma patients are medically stabilized, doctors and families then wait to see whether they will wake up. As months go by, the chance for coming out of a coma decreases rapidly and hospital bills soar. Three hundred days of hospitalization - the average length of stay for serious coma cases - can cost $450,000, which is paid by taxpayers if a patient is uninsured. "There's no doubt the cost is increasing because the new technology is helping more people stay alive," says Sally Richardson, who oversees coma-related health care for the U.S. Health Care Finance Administration.>> _________________ These patients might very well have their coma states shortened significantly by use of HU-211 and their subsequent chances improved for rehabilitation. The number is not insignificant. In a large sampling, Newsday found that 1/5 of coma patients ended up as long-term coma patients because no suitable medication intervention was available for the hours immediately following injury. HU-211 could be that drug. That is worth national coverage --absolutely. So a news story that would explain the after-care cost of such injury AND then extend that picture further by linking HU-211 to additional brain injuries (like stroke, Parkinson's, etc.) will make it clear how revolutionary this drug could be. News of the unblinding for HU-211 is supposed to be announced prior to the market opening. Even if the Street doesn't take notice initially, if the results are good enough investors will take notice eventually. Good luck to us all. Ariella